Prof Wassilios Meissner
MD PhD
Neurologist
University of Bordeaux,
Visiting Professor
New Zealand Brain Research Institute, Christchurch
I am a Neurologist, with subspecialty expertise in Movement Disorders and particular interest in Parkinson’s disease (PD) and atypical parkinsonian disorders such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP). I am currently on a research leave at the NZBRI and have a visiting appointment at the University of Otago. The main goal of my research leave is to learn more about eye movement control in healthy subjects and patients with parkinsonian disorders.
My main affiliation is with the University of Bordeaux in France where I am Professor of Neurology since 2012. Within my clinical activities, I am director of the PD Expert Centre Bordeaux and co-chair of the French Reference Centre for MSA.
My current research focuses on biological and clinical markers of disease progression in PD and MSA, as well as the development of new preclinical models and treatments for PD and MSA in a translational approach. Within my current research activities, I have recently completed a phase 1 study with two innovative vaccines directed against alpha-synuclein in patients with MSA (http://sympath-project.eu) and coordinate the European ARTEMIS consortium (http://www.erare.eu/financed-projects/artemis).
Publications
Provided on request for non-commercial personal use by researchers.
2023
Blommer, J., Pitcher, T., Mustapic, M., Eren, E., Yao, P. J., Vreones, M. P., Pucha, K. A., Dalrymple-Alford, J., Shoorangiz, R., Meissner, W. G., Anderson, T., Kapogiannis, D. (2023). Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease. Brain,
146(1), .
10.1093/brain/awac258
Cardoso, F., Goetz, C. G., Mestre, T. A., Sampaio, C., Adler, C. H., Berg, D., ..., ..., Meissner, W.G., ..., ..., Trenkwalder, C. (2023). A statement of the MDS on biological definition, staging, and classification of Parkinson's disease. Movement Disorders.
10.1002/mds.29683
MacAskill, M. R., Pitcher, T. L., Melzer, T. R., Myall, D. J., Horne, K.-L., Shoorangiz, R., Almuqbel, M. M., Livingston, L., Grenfell, S., Pascoe, M. J., Marshall, E. T., Marsh, S., Perry, S. E., Meissner, W. G., Theys, C., Le Heron, C. J., Keenan, R. J., Dalrymple-Alford, J. C., Anderson, T. J. (2023). The New Zealand Parkinson’s Progression Programme. Journal of the Royal Society of New Zealand,
53, .
10.1080/03036758.2022.2111448
Wang, P., Lan, G., Xu, B., Yu, Z., Tian, C., Lei, X., Meissner, W.G., Feng, T., Yang, Y., Zhang, J., 2023. α-Synuclein-carrying astrocytic extracellular vesicles in Parkinson pathogenesis and diagnosis. Translational Neurodegeneration, 12(1), p.40. (2023). Wang, P., Lan, G., Xu, B., Yu, Z., Tian, C., Lei, X., ... & Zhang, J. (2023). α-Synuclein-carrying astrocytic extracellular vesicles in Parkinson pathogenesis and diagnosis. Translational Neurodegeneration,
12(1), .
10.1186/s40035-023-00372-y
2022
Bassil, F., Delamarre, A., Canron, M. H., Dutheil, N., Vital, A., Négrier‐Leibreich, M. L., Bezard, E., Fernagut, P.O., Meissner, W. G. (2022). Impaired brain insulin signalling in Parkinson's disease. Neuropathology and applied neurobiology, 48(1),
e12760..
10.1111/nan.12760
Delamarre, A., Meissner, W. G. (2022). Tracheostomy invasive ventilation for stridor in multiple system atrophy. Parkinsonism & Related Disorders,
97, .
10.1016/j.parkreldis.2022.04.016
Devos, D., Labreuche, J., Rascol, O., Corvol, J. C., Duhamel, A., Guyon Delannoy, P., ... , Moreau, C. (2022). Trial of deferiprone in Parkinson’s disease. New England Journal of Medicine,
387(22), .
Jucaite, A., Cselényi, Z., Kreisl, W. C., Rabiner, E. A., Varrone, A., Carson, R. E., ..., Meissner, W.G. ..., Farde, L. (2022). Glia imaging differentiates multiple system atrophy from Parkinson's disease: a positron emission tomography study with [11C] PBR28 and machine learning analysis. Movement Disorders,
37(1), .
10.1002/mds.28814
Kalampokini, S., Hommel, A. L., Lorenzl, S., Ferreira, J. J., Meissner, W. G., Odin, P., Bloem, B. R., Dodel, R., Schrag, A. E. (2022). Caregiver burden in late-stage parkinsonism and its associations. Journal of Geriatric Psychiatry and Neurology.
10.1177/0891988720968263
Kermorgant, M., Fernagut, P. O., Meissner, W. G., Arvanitis, D. N., N'Guyen, D., Senard, J. M., Pavy-Le Traon, A. (2022). Age and Gender Differences in Cardiovascular Autonomic Failure in the Transgenic PLP-syn Mouse, a Model of Multiple System Atrophy. Frontiers in Neurology,
13, .
10.3389/fneur.2022.874155
Krismer, F., Palma, J. A., Calandra‐Buonaura, G., Stankovic, I., Vignatelli, L., Berger, A. K., Meissner, W. G. (2022). The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations. Movement Disorders,
37(12), .
10.1002/mds.29215
Palma, J. A., Krismer, F., Meissner, W. G., Kuijpers, M., Millar‐Vernetti, P., Perez, M. A., ... , Kaufmann, H. (2022). Patient‐Reported Symptoms in the Global Multiple System Atrophy Registry. Movement Disorders Clinical Practice,
9(7), .
10.1002/mdc3.13544
Pavy‐Le Traon, A., Foubert‐Samier, A., Ory‐Magne, F., Fabbri, M., Senard, J. M., Meissner, W. G., ... , Amar, J. (2022). Ambulatory blood pressure and drug treatment for orthostatic hypotension as predictors of mortality in patients with multiple system atrophy. European Journal of Neurology,
29(4), .
10.1111/ene.15232
Proust-Lima, C., Saulnier, T., Philipps, V., Traon, A. P. L., Péran, P., Rascol, O., Meissner, W. G., Foubert-Samier, A. (2022). Describing complex disease progression using joint latent class models for multivariate longitudinal markers and clinical endpoints. arXiv, .
10.48550/arXiv.2202.05124
Wenning, G. K., Stankovic, I., Vignatelli, L., Fanciulli, A., Calandra‐Buonaura, G., Seppi, K., .., Meissner, W.G, ..., Kaufmann, H. (2022). The movement disorder society criteria for the diagnosis of multiple system atrophy. Movement Disorders,
37(6), .
10.1002/mds.29005
2020
Adrianus, L., Meinders, M., Weerkamp, N., Richinger, C., Schmotz, C., Lorenzl, S., Dodel, R., Coelho, M., Ferreira, J., Tison, F., Boraud, T., Meissner, W. G., Rosqvist, K., Timpka, J., Odin, P., Wittenberg, M., Bloem, B., Koopmans, R., Schrag, A. (2020). Optimizing treatment in undertreated late-stage parkinsonism: a pragmatic randomized trial. Journal of Parkinson’s Disease,
10, .
10.3233/JPD-202033
Grimm, M. J., Respondek, G., Stamelou, M., Arzberger, T., Ferguson, L., Gelpi, E., Giese, A., Grossman, M., Irwin, D., Pantelyat, A., Rajput, A., Roeber, S., van Swieten, J., Troakes, C., Meissner, W. G., Nilsson, C., Piot, I., Compta, Y., Rowe, J., Höglinger, G. (2020). Clinical conditions “Suggestive of Progressive Supranuclear Palsy” — diagnostic performance. Movement Disorders,
35, .
10.1002/mds.28263
Hommel, A. L., Meinders, M. J., Lorenzl, S., Dodel, R., Coelho, M., Ferreira, J. J., Laurens, B., Spampinato, U., Meissner, W. G., Rosqvist, K., Timpka, J., Odin, P., Wittenberg, M., Bloem, B., Koopmans, R., Schrag, A., Care of Late‐Stage Parkinsonism Consortium. (2020). The prevalence and determinants of neuropsychiatric symptoms in late‐stage parkinsonism. Movement Disorders Clinical Practice,
7, .
10.1002/mdc3.12968
Hommel, A. L., Meinders, M. J., Weerkamp, N. J., Richinger, C., Schmotz, C., Lorenzl, S., Dodel, R., Coelho, M., Ferreira, J., Tison, F, Boraud, T., Meissner, W. G., Rosqvist, K., Timpka, J., Odin, P., Wittenberg, M., Bloem, B., Koopmans, R., Schrag, A. (2020). Optimizing treatment in undertreated late-stage parkinsonism: a pragmatic randomized trial. Journal of Parkinson's disease,
.
10.3233/JPD-202033
Lopez‐Cuina, M., Guerin, P. A., Canron, M. H., Delamarre, A., Dehay, B., Bezard, E., Meissner, W. G., Fernagut, P. O. (2020). Nilotinib fails to prevent synucleinopathy and cell loss in a mouse model of multiple system atrophy. Movement Disorders,
35, .
10.1002/mds.28034
Markaki, I., Bergström, S., Tsitsi, P., Remnestål, J., Månberg, A., Hertz, E., Paslawski, W., Sorjonen, K., Uhlén, M., Mangone, G., Carvalho, S., Rascol, O., Meissner, W. G., Magnin, E., Wüllner, U., Corvol, J., Nilsson, P., Svenningsson, P. (2020). Cerebrospinal fluid levels of Kininogen‐1 indicate early cognitive impairment in Parkinson's disease. Movement Disorders,
35, .
10.1002/mds.28192
Meissner, W. G., Traon, A. P. L., Foubert‐Samier, A., Galabova, G., Galitzky, M., Kutzelnigg, A., ... , Rascol, O. (2020). A Phase 1 randomized trial of specific active α‐synuclein immunotherapies PD01A and PD03A in multiple system atrophy. Movement Disorders,
35, .
10.1002/mds.28218
Painous, C., van Os, N. J. H., Delamarre, A., Michailoviene, I., Marti, M. J., van de Warrenburg, B. P., Meissner, W. G., …, Tijssen, M. A. (2020). Management of rare movement disorders in Europe: outcome of surveys of the European Reference Network for Rare Neurological Diseases. European Journal of Neurology,
27, .
10.1111/ene.14302
Phokaewvarangkul, O., Vorachit, S., Phoumindr, A., Keosodsay, S., Postuma, R. B., Meissner, W. G., Bhidayasiri, R. (2020). Addressing knowledge gaps in Parkinson’s disease: a report on the Movement Disorder Society’s Centre-to-Centre initiative to improve Parkinson’s disease services in Lao People’s Democratic Republic. BMC Medical Education,
20, .
10.1186/s12909-020-02161-x
Rascol, O., Negre-Pages, L., Damier, P., Delval, A., Derkinderen, P., Destée, A., Fabbri, M., Meissner, W.G., Rachdi, A., Tison, F. and Perez-Lloret, S. (2020). Utilization patterns of amantadine in Parkinson’s disease patients enrolled in the French COPARK study. Drugs & Aging,
37, .
10.1007/s40266-019-00740-2
Respondek, G., Grimm, M. J., Piot, I., Arzberger, T., Compta, Y., Englund, E., Ferguson, L., Gelpi, E., Roeber, S., Giese, A., Grossman, M., Irwin, D., Meissner, W. G., Nilsson, C., Pantelyat, A., Rajput, A., van Swieten, J., Troakes, C., Höglinger, G., Whitwell, J. L. (2020). Validation of the Movement Disorder Society criteria for the diagnosis of 4‐repeat tauopathies. Movement Disorders,
35, .
10.1002/mds.27872
Yu, Z., Shi, M., Stewart, T., Fernagut, P. O., Huang, Y., Tian, C., …, Meissner, W.G., Zhang, J. (2020). Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. Brain,
143, .
10.1093/brain/awaa110
2019
Delamarre, A., Tison, F., Li, Q., Galitzky, M., Rascol, O., Bezard, E., Meissner, W. G. (2019). Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease. Journal of Neural Transmission,
126, .
10.1007/s00702-019-02015-x
Grimm, M. J., Respondek, G., Stamelou, M., Arzberger, T., Ferguson, L., Gelpi, E., Giese, A., Grossman, M., Irwin, D. J., Pantelyat, A., Rajput, A., Roeber, S., van Swieten, J. C., Troakes, C., Antonini, A., Bhatia, K. P., Colosimo, C., van Eimeren, T., Kassubek, J., Levin, J., Meissner, W. G., Nilsson, C., Oertel, W. H., Piot, I., Poewe, W., Wenning, G. K., Boxer, A., Golbe, L. I., Josephs, K. A., Litvan, I., Morris, H. R., Whitwell, J. L., Compta, Y., Corvol, J. C., Lang, A. E., Rowe, J. B., Höglinger, G. U., Movement Disorder Society-endorsed PSP Study Group (2019). How to apply the Movement Disorder Society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders.
10.1002/mds.27666
Vergnet, S., Hives, F., Foubert-Samier, A., Payoux, P., Fernandez, P., Meyer, M., ..., Meissner, W. G. (2019). Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. Parkinsonism & Related Disorders.
10.1016/j.parkreldis.2019.02.006
Abstracts and Short papers
2020
Delamarre, A., Rigalleau, V., Meissner, W. G. (2020). Insulin resistance, diabetes and Parkinson’s disease: the match continues. Parkinson’s and Related Disorders,
80, .
10.1016/j.parkreldis.2020.10.013
Meissner, W. G., Höglinger, G. U. (2020). Looking into the prediagnostic phase of progressive supranuclear palsy. Parkinsonism and Related Disorders, .
10.1016/j.parkreldis.2020.04.006
![Download Glia imaging differentiates multiple system atrophy from Parkinson's disease: a positron emission tomography study with [11C] PBR28 and machine learning analysis.](/resources/publications/711/Jucaite_Movement-Disorders_2022.pdf.jpeg)
